Shaanxi Kaisheng Capital Management Co.,Ltd
Ruiying Deng
Investment DirectorShanghai Fenglin Biomedical Development Co. Ltd
Fenglin Biomedical Center (BioFM) is an innovation platform based in Xuhui Shanghai, which functions as the China soft-landing gateway for oversea bio-medical companies. It provides working spaces in downtown area in a flexible manner and helps clients increase their business value with professional services and by leveraging innovative resources including academics, hospitals, industries and venture capitals in the region. Different from the traditional accelerators and incubators, BioFM aims to be a boutique and unique service provider especially for bio-medical entrepreneurs, doctors, and scientists, while helping overseas companies and start-ups to develop their business in China quicker and better
Richard Tao
Mr / Project ManagerShanghai Henlius Biotech
Starting from biosimilar, Henlius presses forward with novel mAb products and immuno-oncology combination therapies with proprietary anti-PD-1 and PD-L1 mAbs as backbone. Henlius establishes a diversified product pipeline of biosimilars, bio-innovative drugs and combination therapies, and builds an integrated platform covering the whole product lifecycle including R&D, commercial-scale production and commercialization.
Keywords : Cancer, Oncology, Biologics, Biosimilar, BioInnovative, Biobetter, Monoclonal Antibody, Mabs, Tumors, Immuno oncology, PD1, PD-L1, EGFR, VEGF, HER2,